Projects per year
Fingerprint Dive into the research topics where David Alland is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 8 Similar Profiles
Mycobacterium tuberculosis
Medicine & Life Sciences
Tuberculosis
Medicine & Life Sciences
Rifampin
Medicine & Life Sciences
Isoniazid
Medicine & Life Sciences
Mutation
Medicine & Life Sciences
Ethambutol
Medicine & Life Sciences
Multidrug-Resistant Tuberculosis
Medicine & Life Sciences
Sputum
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2009 2021
Novel Biomarkers To Shorten Tb Treatment
National Institutes of Health (NIH)
6/22/16 → 5/31/21
Project: Research project
Biomarkers
Tuberculosis
Therapeutics
Pharmacokinetics
Genome
Process And Pathway Based Discovery Of Novel Anti-Tb Drugs
National Institutes of Health (NIH)
4/25/14 → 4/1/15
Project: Research project
Cell Wall
Pharmaceutical Preparations
DNA Gyrase
Mycobacterium tuberculosis
Respiration
Pre-Clinical Development Of An Advanced Genexpert Test For Drug Resistant Mtb
National Institutes of Health (NIH)
4/1/14 → 3/31/19
Project: Research project
Rifampin
Tuberculosis
Pharmaceutical Preparations
Multidrug-Resistant Tuberculosis
Fluoroquinolones
Discovery And Validation Of Drug Targets In Vulnerable Populations
National Institutes of Health (NIH)
3/1/14 → 2/28/19
Project: Research project
Vulnerable Populations
Mycobacterium tuberculosis
Cell Wall
Pharmaceutical Preparations
Respiration
Discovery And Validation Of Drug Targets In Vulnerable Pathways Of Mtb
National Institutes of Health (NIH)
3/1/14 → 2/29/16
Project: Research project
Mycobacterium tuberculosis
Cell Wall
Pharmaceutical Preparations
Respiration
bedaquiline
Research Output 1992 2019
Lack of association of novel mutation Asp397Gly in aftB gene with ethambutol resistance in clinical isolates of Mycobacterium tuberculosis
Giri, A., Safi, H., Cabibbe, A. M., Gupta, S., Narang, A., Tyagi, G., Shrivastava, K., Kumar, C., Kumar Sharma, N., Lingaraju, S., Trovato, A., Battaglia, S., Cirillo, D. M., Bose, M., Alland, D. & Varma-Basil, M., Mar 1 2019, In : Tuberculosis. 115, p. 49-55 7 p.Research output: Contribution to journal › Article
Ethambutol
Mycobacterium tuberculosis
Mutation
Genes
Microbial Sensitivity Tests
1
Citation
(Scopus)
Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent
Gallardo-Macias, R., Kumar, P., Jaskowski, M., Richmann, T., Shrestha, R., Russo, R., Singleton, E., Zimmerman, M. D., Ho, H. P., Dartois, V., Connell, N., Alland, D. & Freundlich, J., Feb 15 2019, In : Bioorganic and Medicinal Chemistry Letters. 29, 4, p. 601-606 6 p.Research output: Contribution to journal › Article
Nitrofurans
Antitubercular Agents
Cytotoxicity
Vero Cells
Pharmacokinetics
The authors reply
Colangeli, R., Kim, S. & Alland, D., Jan 10 2019, In : New England Journal of Medicine. 380, 2, p. 197-198 2 p.Research output: Contribution to journal › Letter
Transmission phenotype of mycobacterium tuberculosis strains is mechanistically linked to induction of distinct pulmonary pathology
Verma, S., Bhatt, K., Lovey, A., Ribeiro-Rodrigues, R., Durbin, J., Jones-López, E. C., Palaci, M., Vinhas, S. A., Alland, D., Dietze, R., Ellner, J. J. & Salgame, P., Mar 1 2019, In : PLoS pathogens. 15, 3, e1007613.Research output: Contribution to journal › Article
Open Access
Mycobacterium tuberculosis
Pathology
Phenotype
Lung
Macrophages
7
Citations
(Scopus)
Bacterial factors that predict relapse after tuberculosis therapy
Colangeli, R., Jedrey, H., Kim, S., Connell, R., Ma, S., Venkata, U. D. C., Chakravorty, S., Gupta, A., Sizemore, E. E., Diem, L., Sherman, D. R., Okwera, A., Dietze, R., Boom, W. H., Johnson, J. L., Kenzie, W. R. M. & Alland, D., Aug 30 2018, In : New England Journal of Medicine. 379, 9, p. 823-833 11 p.Research output: Contribution to journal › Article
Microbial Sensitivity Tests
Tuberculosis
Recurrence
Isoniazid
Rifampin